The Cost-Effective Solution for Diabetic Foot Care

Reducing NHS Costs through AOTI’s TWO2 Therapy

A recent peer-reviewed study has highlighted the significant cost-effectiveness of AOTI’s multi-modality oxygen therapy in managing diabetic foot ulcers (DFUs). The study, published in the Journal of Diabetic Complications, was authored by UK-based health economists and clinical experts in diabetic foot care. The study’s findings have led to the inclusion of AOTI’s therapy in the new NHS framework agreement for advanced wound care.

• DFUs are a leading cause of morbidity and lower-limb amputations among diabetics, with up to one third of patients affected in their lifetime.
• Non-healing ulcers account for the bulk of related costs, with around 66% failing to heal within a year and approximately half developing infections.

The total cost of diabetic foot disease in England was estimated to represent nearly 1% of the NHS’s projected £192bn budget for 2025. AOTI’s TWO2 therapy offers a cost-effective solution for managing DFUs, which can significantly reduce overall diabetic foot care costs for the NHS in England. AOTI stated that the NHS framework inclusion would support broader adoption of its therapy, and was aligned with efforts to reduce amputation rates and long-term care costs. By incorporating AOTI’s therapy, the NHS can start to realise substantial cost savings.

“It is exciting to see acknowledgement of the clinical and health economic benefits delivered by our unique cyclical-pressure TWO2 therapy with its inclusion in the new framework agreement for advanced wound care,” said president and chief executive officer Dr Mike Griffiths.

According to Dr Griffiths, the benefits of AOTI’s therapy are driven by significantly reduced wound recurrence, hospitalisations, and amputations. These outcomes translate to improved quality of life for patients living with non-healing foot ulcers.

These benefits are a significant advantage of AOTI’s therapy, and demonstrate its potential to improve patient outcomes while reducing healthcare costs. The inclusion of AOTI’s therapy in the new NHS framework agreement is a major step forward in the management of diabetic foot ulcers. By making this therapy more accessible to patients, the NHS can start to realise the substantial cost savings that are promised by AOTI’s treatment. Key Highlights
* AOTI’s TWO2 therapy is cost-effective and can significantly reduce overall diabetic foot care costs for the NHS in England.
* The therapy is aligned with efforts to reduce amputation rates and long-term care costs.
* The NHS framework inclusion supports broader adoption of the therapy, making it easier for patients to access AOTI’s proven limb-saving outcomes.

* Diabetic foot ulcers (DFUs): A leading cause of morbidity and lower-limb amputations among diabetics. * AOTI’s TWO2 therapy: A multi-modality oxygen therapy that offers a cost-effective solution for managing DFUs.

The statistics highlight the significant burden that DFUs place on the NHS. By incorporating AOTI’s therapy into the new NHS framework agreement, the NHS can start to address this burden and reduce the associated costs.